Avalere to Support Boehringer Ingelheim in Outcomes-Based Contracting
Summary
Avalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
As private payers rapidly shift from volume to value-based payments, they seek contracts that reward outcomes to improve patient clinical care. Our agreement will support this transformation for Boehringer Ingelheim’s diabetes alliance with Eli Lilly.
This agreement utilizes Inovalon and Avalere’s combined breadth of healthcare capabilities to generate new insights about real-world diabetes care, identify opportunities for improved outcomes, and deploy platforms for provider- and patient-level interventions.
By leveraging innovative technologies currently in use with more than 100 existing health plan customers, the partnership will leverage a more holistic and integrated support to outcomes-based contracting that will better align with payer needs and help improve quality and clinical/economic outcomes.
Related Content
